<DOC>
	<DOCNO>NCT00967772</DOCNO>
	<brief_summary>The safety/tolerability pharmacokinetics ( PK ) Naftopidil ( commercial name : Flivas ) oral administration investigated Korean healthy male volunteer . All volunteer assign 2 group administer low single dose tablet ( Period 1 ) . After one week 's wash-over period , volunteer take high dosage ( Period 2 ) .</brief_summary>
	<brief_title>The Safety/Tolerability Pharmacokinetics ( PKs ) Naftopidil Korean Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Naftopidil</mesh_term>
	<criteria>Healthy male subject , 2045 year inclusive Weight 55 kg inclusive Ideal Body Weight ( IBW ) 20 % +20 % inclusive Written inform consent give Hypersensitivity drug ( aspirin , antibiotic ) include naftopidil History presence clinically significant liver kidney disease , gastrointestinal , cardiovascular , respiratory , endocrinal , musculoskeletal , neurologic/psychiatric , urinary , hematological , oncological pathology Have history drug abuse , show positive drug abuse urine screen Have participate another clinical study within 2 month prior enter inth study Are consider ineligible investigator due clinical laboratory result relevant reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
</DOC>